Concordance in pathological response to neoadjuvant chemotherapy between invasive and noninvasive components of primary breast carcinomas

Breast Cancer

Volumn 9, Issue 1, 2002, Pages 75-81

  Matsuo, Kaneyuki ^a   Fukutomi, Takashi ^a   Watanabe, Toru ^a   Hasegawa, Tadashi ^b   Tsuda, Hitoshi ^c   Akashi Tanaka, Sadako ^a  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

^b NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^c NATIONAL DEFENSE MEDICAL COLLEGE   (Japan)

Author keywords

Breast Cancer; Invasive component; Neoadjuvant chemotherapy; Noninvasive component; Pathological response

Indexed keywords

ANTINEOPLASTIC AGENT; DOCETAXEL; DOXORUBICIN; DRUG DERIVATIVE; PACLITAXEL; TAXOID;

ADJUVANT THERAPY; ARTICLE; BREAST TUMOR; DRUG ADMINISTRATION; FEMALE; HUMAN; LUNG CARCINOMA; PAGET NIPPLE DISEASE; PATHOLOGY; SQUAMOUS CELL CARCINOMA; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, INTRADUCTAL, NONINFILTRATING; CARCINOMA, LOBULAR; CARCINOMA, SQUAMOUS CELL; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; NEOADJUVANT THERAPY; PACLITAXEL; TAXOIDS; TREATMENT OUTCOME;

EID: 0036043353     PISSN: 13406868     EISSN: 18804233     Source Type: Journal    
DOI: 10.1007/BF02967551     Document Type: Article

References (26)

1. Hortobagyi GN: Multidisciplinary management of advanced primary and metastatic breast cancer. Cancer 74:416-423, 1994. (Pubitemid 24187658)
2. Hortobagyi GN: Recent progress in the clinical development of docetaxel (taxotere). Semin Oncol 26:32-36, 1999. (Pubitemid 29340755)
3. Honkoop AH, van Diest PJ, linn SC, et al: Prognostic role of clinical, pathological and biological characteristics in patients with locally advanced breast cancer. Br J Cancer 77:621-626, 1998. (Pubitemid 28059470)
4. Powels TJ, Hickish TF, Makris TF, et al: Randomized trial of chemoendocrine therapy started before or after surgery for treatment of primary breast cancer. J Clin Oncol 13:547-552, 1995.
5. Kurerer HM, Newmann LA, Smith TL, et al: Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol 17:460-469, 1999. (Pubitemid 29075229)
6. Markis A, Powles TJ, Dowsett CK, et al: Prediction of response to neoadjuvant chemoendocrine therapy in primary breast carcinomas. Clin Cancer Res 3:593-600, 1997. (Pubitemid 27211838)
7. Gusterson BA, Gelber RD, Goldhirsch A, et al: Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group. J Clin Oncol 10:1049-1056, 1992.
8. Chevallier B, Roche H, Olivier JP, et al: Inflammatory breast cancer. Pilot study of intensive induction chemotherapy (FEC-HD). Results in high histological response rate. Am J Clin Oncol 16:223-228, 1993. (Pubitemid 23184384)
9. Honkoop AH, van Diest PJ, de Jong JS, et al: Prognostic role of clinical, pathological and biological characteristics in patients with locally advanced breast cancer. Br J Cancer 77:621-626, 1998. (Pubitemid 28059470)
10. Kurosumi M. Akiyama F, Tsuda H, et al: Histopathological criteria for assessment of therapeutic response in breast cancer. Breast Cancer 1:1-2, 2001.
11. Francis ES, Shari LA, Larry JF, et al: Effects of preoperative chemotherapy on the morphology of respectable breast carcinoma. Mod Pathol 9:893-900, 1996.
12. Ando M, Watanabe T, Nagata K, et al: Efficacy of docetaxel 60mg/m2 in patients with metastatic breast cancer according to the status of anthracycline resistance. J Clin Oncol 19:336-342, 2001. (Pubitemid 32112844)
13. Clinical response to chemotherapy. In: World Health Organization ed, WHO handbook for reporting results of cancer treatment. Offset Publication, Geneva, pp 14-15, 1976.
14. Costa SD, Minckmiz G, Raab G, et al: The role of docetaxel (taxotere) in neoadjuvant chemotherapy of breast cancer. Semin Oncol 26:24-31, 1999. (Pubitemid 29340754)
15. Machiavelli MR, Romero AO, Perez JE, et al: Prognostic significance of pathological response of primary tumor and metastatic lymph node after neoadjuvant chemotherapy for locally advanced breast carcinoma. The Cancer J from scie Am 4:125-131, 1998. (Pubitemid 29090716)
16. Brifford M, Spyratos F, Tubiana-Hulin M, et al: Sequential cytopunctures during preoperative chemotherapy for primary breast carcinoma: Cytomorphorogic changes, initial tumor ploidity, and tumor regression. Cancer 63:631, 1989.
17. Bonadonna G, Veronesi U, Brambillia C, et al: Primary chemotherapy to avoid mastectomy in tumors with diameters of three centimeters or more. J Nalt Cancer Inst 82:1539, 1990.
18. Morrow M, Braverman A, Thelmo W, et al: Multimodal therapy for locally advanced breast cancer. Arch Surg 121:1291, 1986.
19. Frierson HF Jr, Fechner RE: Histologic grade of locally advanced infiltrating ductal carcinoma after treatment with induction chemotherapy. Am J Clinc Pathol 102:154, 1994.
20. Kennedy S, Merino MJ, Swain SM, et al: The effects of hormonal and chemotherapy on tumoral and nonneoplastic breast tissue. Hum Pathol 21:192, 1990.
21. Silverberg SG, Chitale AR: Assessment of significance of proportions of intraductal and infiltrating tumor growth in ductal carcinoma of the breast. Cancer 32:830, 1973.
22. Hsu SM, Raine L, Franger H: Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: A comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem 29:830, 1981.
23. Chevallier B, Roche H, Oliver JP, et al: Inflammatory breast cancer. Pilot study of intensive induction chemotherapy (FEC-HD). Results in a high histologic response rate. Am J Clin Oncol 16:223-228, 1997. (Pubitemid 23184384)
24. Monir HE, Mohamed MM, Hussein MK, et al: Pathological assessment of the response of locally advanced breast cancer to neoadjuvant chemotherapy and its implications for surgical management Surg Today 30:249-254, 2000.
25. Kuerer HM, Newman LA, Smith TL, et al: Clinical course of breast cancer patients with complete pathological primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol 17:460-469, 1999. (Pubitemid 29075229)
26. 18F]-fluorodeoxy-D-glucose to predict the pathologic response pf breast cancer to primary chemotherapy. J Clin Oncol 18:1676-1688, 2000. (Pubitemid 30220546)